Skip to main content

Liebowitz Social Anxiety Scale Clinician/Self-Report

Liebowitz Social Anxiety Scale Clinician/Self-Report

(LSAS-CR/SR; Cox, Ross, Swinson, & Direnfeld,  1998; Liebowitz, 1987).

The LSAS-CR/SR is a 24-item clinician- or self-report measure assessing fear and avoidance of social situations in adults.  The LSAS-CR/SR can be used as a screening tool to monitor symptom change over time (Heimberg et al., 1999). The LSAS has a separate version for children and adolescents (LSAS-CA, Masia-Warner, Storch, Pincus, Klein & Heimberg, 2003), as well as a brief child and adolescent version (Shachar, Aderka, & Gilboa-Shechtman, 2013). The LSAS-CR/SR both consist of two subscales: public performance and social interaction. Example items include, “Telephoning people in public” and “Talking to people in authority.” Each item is rated for both fear and avoidance. Fear is rated from zero (“none”) to three (“severe”). Avoidance is rated from zero (“never”) to three (“usually, 68% - 100% of the time”). The LSAS-CR demonstrates good to excellent internal consistency (α=.81-.96; Heimberg et al., 1999). The LSAS-SR demonstrates good test-retest reliability over a period of 12 weeks (r = .83). The LSAS-CR demonstrates convergent validity with the Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998), the Social Phobia Scale (SPS; Mattick & Clarke, 1998), the Fear of Negative Evaluation Scale (FNES; Watson & Friend, 1969), and the social phobia subscale of the Fear Questionnaire (FQ; Marks & Mathews, 1979). It also demonstrates divergent validity with the Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). The LSAS-SR demonstrates convergent validity with the LSAS-CR, the Social Phobia and Anxiety Inventory (SPAI), and the Self-Statements During Public Speaking Scale (SPSS; Hofmann & Dibartolo, 2000). It also demonstrates moderate significant correlation with the BDI (Baker, Heinrichs, Kim, & Hofmann, 2002). The LSAS-CR/SR are available online (http://healthnet.umassmed.edu/mhealth/LiebowitzSocialAnxietyScale.pdf & http://asp.cumc.columbia.edu/SAD/).  The LSAS-CA is available via (Carrie.Masia@nyumc.org).

Comments

Popular posts from this blog

ADVOKATE: A Tool for Assessment of Eyewitness Evidence

ADVOCATE: A Tool for Assessment of Eyewitness Evidence It is a tool designed to assess the eyewitness evidence that how much it is reliable. It requires the user to respond to several statements/questions. Forensic psychologist, police or investigative officer can do it. The mnemonic ADVOKATE stands for: A = amount of time under observation (event and act) D = distance from suspect V = visibility (night-day, lighting) O = obstruction to the view of the witness K = known or seen before when and where (suspect) A = any special reason for remembering the subject T = time-lapse (how long has it been since witness saw suspect) E = error or material discrepancy between the description given first or any subsequent accounts by a witness.  Working with suspects (college.police.uk)

Diagnostic test for catatonia, the lorazepam challenge test

Benzodiazepines are the mainstay of the treatment of catatonia and are also helpful as a diagnostic probe. A positive Lorazepam Challenge Test validates the diagnosis of catatonia. After we examine the patient for signs of catatonia, 1 or 2 mg of lorazepam is administered intravenously. After 5 minutes, the patient is re-examined. If there has been no change, a second dose is given, and the patient is again reassessed (46, 78). A positive response is a marked reduction (e.g., at least 50%) of catatonic signs and symptoms, as measured with a standardized rating scale. Favorable responses usually occur within 10 min (46). If lorazepam is given intramuscularly or per os, the interval for the second dose should be longer: 15′ and 30′, respectively. Many clinicians will share the experience that a “lorazepam test” not only confirms the diagnosis of catatonia but that it also makes the underlying psychopathology apparent “by permitting mute patients to speak” (79). Analogous to the lorazepa

Classification of Depression According to the ICD-10

A first depressive episode, duration at least15 days →depressive episode (F32)  A first depressive episode, severe and rapid onset, duration less than 15 days →still depressive episode (F32) A depressive episode can be mild (2 core symptoms, 2 other symptoms from the list) (32.0) moderate (2 core symptoms, 3 or preferably 4 other symptoms) (32.1) Severe (3 core symptoms, 4 other symptoms) without psychotic symptoms (32.2) (no delusion, hallucination or stupor) Severe with psychotic symptoms (above plus either delusions, hallucinations or stupor) (F32.3) Delusions can be mood-congruent or incongruent (neutral delusions e.g. delusions of reference are considered mood incongruent. None of them count towards schizoaffective disorder unless one of the first-rank)  A mild and moderate depressive episode can be  with somatic syndrome (four or more somatic symptoms, or three very severe somatic symptoms) without somatic syndrome (three or less somatic symptoms, not severe)  A severe depressi